Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide Maintenance in Stage IIIB/IV NSCLC
NCT02018523Phase 1Terminated
- Start
- Jun 2014
- Primary completion
- Aug 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lenalidomide in non-small cell lung cancer (NSCLC). Primary endpoint: Progression-Free Survival at 6 months. Started Jun 2014; status: terminated.
02
Drugs
lenalidomide
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02018523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02018523.